India’s Mankind Pharma reported a stronger-than-expected profit for the second quarter of FY24, driven by higher demand for its medications targeting long-term health conditions like diabetes and cardiovascular diseases.
For the quarter ending September 30, the company’s consolidated net profit reached Rs 653 crore ($77.7 million), marking a 30% increase compared to the same period last year. This figure exceeded analysts’ estimates, which had forecasted a profit of Rs 590 crore, according to LSEG data.
The growth was fueled by a rise in revenue from its key chronic illness drugs segment, which now accounts for 35% of total revenue, up from 34% last year. This increase contributed to an overall 14% revenue growth for the quarter.
Mankind Pharma, which also produces Manforce condoms and Prega News pregnancy kits, continues to benefit from the steady demand for its diverse product portfolio.
Spain has proposed a 100% tax on homes bought by non-EU residents as part of…
Sonu Nigam and Vishal Dadlani, two of the biggest names in the Indian music industry,…
Walmart unveils the first redesign of its logo in nearly two decades, balancing nostalgia with…
A new survey finds that 42% of Washington, D.C. managers of the federal government will…
The European Union's scrutiny of X, the social media platform formerly known as Twitter, has…
Toyota's new 2.0-liter turbocharged engine is a game-changer in performance. Expected to produce over 400…